MDWD Stock Analysis: Buy, Sell, or Hold?
MDWD - MediWound Ltd.
$15.16
0.34 (2.29%)
▲
5d:
+3.91%
30d:
+10.17%
90d:
-6.42%
BUY
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When MDWD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MDWD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MDWD shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MDWD is currently trading at $15.16, which is considered extended relative to its 30-day fair value range of $13.81 to $15.02.
Technical Outlook: Technically, MDWD is in a downtrend. Immediate support is located at $13.54, while resistance sits at $16.12.
Market Sentiment: MDWD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.17 (+99.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MDWD is in a downtrend. Immediate support is located at $13.54, while resistance sits at $16.12.
Market Sentiment: MDWD has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $30.17 (+99.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.81 -
$15.02
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 99.0% below Wall St target ($30.17)
Trading Range Analysis
30-Day Trading Range
$13.81 -
$15.02
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.74
(11.5%)
Support & Resistance Levels
Support Level
$13.54
Resistance Level
$16.13
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.83
Wall Street Target
$30.17
(+99.0%)
Revenue Growth (YoY)
-62.7%
Profit Margin
-180.3%
Share & Embed Analysis
Last updated: July 02, 2026 11:40 PM ET
Data refreshes hourly during market hours. Next update: 12:40 AM
Data refreshes hourly during market hours. Next update: 12:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDWD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
